East Windsor, NJ (September 20, 2016) – Sabinsa’s Curcumin C3 Complex® and Curcumin C3 Reduct® received two significant health claims from Health Canada based on the new clinical studies on the respective products.
Curcumin C3 Complex-‐ HELPS SUPPORT HEALTHY SERUM TRIGLYCERIDE LEVELS
Shortly after being chosen for NutraIngredients’s “Best University Research Award” for a clinical study done in Iran, Sabinsa’s Curcumin C3 Complex® received approval from Health Canada for the health claim “SUPPORTS HEALTHY SERUM TRIGLYCERIDE LEVELS, PROVIDES ANTIOXIDANT,” applying to the combination of 500mg of Curcumin C3 Complex® and 5mg of BioPerine (Patented black pepper extract) to be taken twice daily. This claim is supported by a placebo controlled, randomized double blind cross over clinical study showing significant reduction in serum triglyceride concentration in obese subjects. In Canada the Curcumin monograph allows for traditional claims of “Antioxidants, Relief of Joint inflammation;” the new claim on the Curcumin C3 Complex and BioPerine combination adds more health benefits for consumers. Sabinsa holds multiple patents on both Curcumin C3 Complex® and BioPerine®
While studies on Curcuminoids have advanced knowledge of the role of curcumin in the body, it also revealed the transformations which curcumin undergoes in the body, including its conversion into tetrahydrocurcuminoids, which are widely accepted as most active metabolites of curcuminoids. Sabinsa’s Curcumin C3 Reduct® is a relatively new product, standardized to 95% of tetrahydrocurcuminoids, the active metabolite. Based on the studies available on Sabinsa’s Curcumin C3 Reduct®, NNHPD (Natural & Non prescription Health Product Directorate) in Canada approved the claim “PROVIDES ANTIOXIDANTS” for dosage of 100mg C3 REDUCT twice daily. This is the first health claim for a Curcumin metabolite.
